[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100327154":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":21,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":7,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":31,"maxAge":32,"enrollmentInfo":7,"targetDuration":7,"studyType":33,"phases":7,"briefSummary":34,"conditions":35,"keywords":7,"overallStatus":37,"whyStopped":7,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":42,"locationsCount":7},{"fullName":5,"class":6},"Teva Branded Pharmaceutical Products R&D, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Fremanezumab","For patients who enter this program, the monthly dose of fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the patient's weight every 3 months.",[14],"TEV-48125",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Teva Medical Expert, MD","CONTACT","1-888-483-8279","USMedInfo@tevapharm.com",{"type":22,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100327154","fremanezumab-managed-access-program-for-pediatric-patients-100327154",false,"NCT03539393","Fremanezumab Managed Access Program for Pediatric Patients","Fremanezumab (TEV-48125) Compassionate Use Program for Pediatric Patients (6 to 17 Years) With Chronic or Episodic Migraine","Inclusion Criteria:\n\n* Eligible patients may enter this CUP after successfully completing TV48125-CNS-30084 and all End of Study procedures\n* In the opinion of your physician\u002Finvestigator are able to continue IMP (fremanezumab) in a safe and compliant way.\n\nExclusion Criteria:\n\n* Additional criteria may apply, please contact your physician\u002Finvestigator for more information.","ALL","6 Years","17 Years","EXPANDED_ACCESS","This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either episodic or chronic migraine who have successfully completed the Teva sponsored study TV48125-CNS-30084 (SPACE study).",[36],"Migraine","AVAILABLE","2026-07-23",{"date":40,"type":41},"2026-07-27","ACTUAL",{"name":43,"class":6},"Teva Branded Pharmaceutical Products R&D LLC"]